MaxCyte signs licensing deal with Myeloid Therapeutics

MaxCyte announced on Monday that itself and Myeloid Therapeutics, a company harnessing and reprogramming myeloid cells to treat cancers, had signed a clinical and commercial licensing agreement.

The AIM-traded firm said Myeloid would obtain non-exclusive clinical and commercial rights to use its ‘Flow Electroporation’ technology and ‘ExPERT’ platform.

It said the agreement would enable Myeloid to advance its pipeline programmes, including for engineered cell therapies targeting solid tumors, T-cell lymphoma and glioblastoma.

In return, MaxCyte would be entitled to receive undisclosed development and approval milestones, and sales-based payments, along with other licensing fees.

MaxCute said Myeloid's ‘ATAK’ platform leveraged myeloid cells to help patients fighting cancers that, until now, had been “very difficult” to treat.

By targeting myeloid cells, the technology allowed for “diverse applications”, with Myeloid's pipeline expansion ongoing.

“We are proud to support Myeloid's work and are excited about the company's novel approach to engineering and harnessing the innate capabilities of the myeloid cell,” said MaxCyte president and chief executive officer Doug Doerfler.

“This agreement represents an important achievement for MaxCyte as it expands the use of our next-generation technology platform to support engineering in novel cell types.

“Myeloid's ATAK technology is being developed for several critical applications in cancer.”

At 1206 GMT, shares in MaxCyte were up 1.67% at 610p.